Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
Br J Anaesth ; 128(2): 272-282, 2022 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-34872717

RESUMEN

BACKGROUND: Anaemia is common and associated with poor outcomes in survivors of critical illness. However, the optimal treatment strategy is unclear. METHODS: We conducted a multicentre, feasibility RCT to compare either a single dose of ferric carboxymaltose 1000 mg i.v. or usual care in patients being discharged from the ICU with moderate or severe anaemia (haemoglobin ≤100 g L-1). We collected data on feasibility (recruitment, randomisation, follow-up), biological efficacy, and clinical outcomes. RESULTS: Ninety-eight participants were randomly allocated (49 in each arm). The overall recruitment rate was 34% with 6.5 participants recruited on average per month. Forty-seven of 49 (96%) participants received the intervention. Patient-reported outcome measures were available for 79/93 (85%) survivors at 90 days. Intravenous iron resulted in a higher mean (standard deviation [sd]) haemoglobin at 28 days (119.8 [13.3] vs 106.7 [14.9] g L-1) and 90 days (130.5 [15.1] vs 122.7 [17.3] g L-1), adjusted mean difference (10.98 g L-1; 95% confidence interval [CI], 4.96-17.01; P<0.001) over 90 days after randomisation. Infection rates were similar in both groups. Hospital readmissions at 90 days post-ICU discharge were lower in the i.v. iron group (7/40 vs 15/39; risk ratio=0.46; 95% CI, 0.21-0.99; P=0.037). The median (inter-quartile range) post-ICU hospital stay was shorter in the i.v. iron group but did not reach statistical significance (5.0 [3.0-13.0] vs 9.0 [5.0-16.0] days, P=0.15). CONCLUSION: A large, multicentre RCT of i.v. iron to treat anaemia in survivors of critical illness appears feasible and is necessary to determine the effects on patient-centred outcomes. CLINICAL TRIAL REGISTRATION: ISRCTN13721808 (www.isrctn.com).


Asunto(s)
Anemia/tratamiento farmacológico , Compuestos Férricos/administración & dosificación , Hematínicos/administración & dosificación , Maltosa/análogos & derivados , Administración Intravenosa , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Cuidados Críticos , Estudios de Factibilidad , Femenino , Estudios de Seguimiento , Hemoglobinas/análisis , Humanos , Tiempo de Internación , Masculino , Maltosa/administración & dosificación , Persona de Mediana Edad , Readmisión del Paciente/estadística & datos numéricos , Medición de Resultados Informados por el Paciente , Adulto Joven
2.
Med ; 2(2): 164-179.e12, 2021 02 12.
Artículo en Inglés | MEDLINE | ID: mdl-33665641

RESUMEN

BACKGROUND: How specific nutrients influence adaptive immunity is of broad interest. Iron deficiency is the most common micronutrient deficiency worldwide and imparts a significant burden of global disease; however, its effects on immunity remain unclear. METHODS: We used a hepcidin mimetic and several genetic models to examine the effect of low iron availability on T cells in vitro and on immune responses to vaccines and viral infection in mice. We examined humoral immunity in human patients with raised hepcidin and low serum iron caused by mutant TMPRSS6. We tested the effect of iron supplementation on vaccination-induced humoral immunity in piglets, a natural model of iron deficiency. FINDINGS: We show that low serum iron (hypoferremia), caused by increased hepcidin, severely impairs effector and memory responses to immunizations. The intensified metabolism of activated lymphocytes requires the support of enhanced iron acquisition, which is facilitated by IRP1/2 and TFRC. Accordingly, providing extra iron improved the response to vaccination in hypoferremic mice and piglets, while conversely, hypoferremic humans with chronically increased hepcidin have reduced concentrations of antibodies specific for certain pathogens. Imposing hypoferremia blunted the T cell, B cell, and neutralizing antibody responses to influenza virus infection in mice, allowing the virus to persist and exacerbating lung inflammation and morbidity. CONCLUSIONS: Hypoferremia, a well-conserved physiological innate response to infection, can counteract the development of adaptive immunity. This nutrient trade-off is relevant for understanding and improving immune responses to infections and vaccines in the globally common contexts of iron deficiency and inflammatory disorders. FUNDING: Medical Research Council, UK.


Asunto(s)
Deficiencias de Hierro , Trastornos del Metabolismo del Hierro , Animales , Hepcidinas/genética , Humanos , Inmunidad Humoral , Hierro , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Porcinos , Vacunación
3.
J Pediatr Hematol Oncol ; 42(4): e235-e237, 2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-30933022

RESUMEN

Diamond-Blackfan Anemia (DBA) is a rare inherited form of pure red cell aplasia that usually manifests in infancy or early childhood, and is characterized by normochromic macrocytic anemia and bone marrow erythroblastopenia. The majority of DBA cases are associated with mutations in ribosomal protein genes. Here, we describe a Lebanese girl with RPL5-mutated DBA unresponsive to steroid treatment who died from complications following late hematopoietic stem cell transplantation performed at the age of 15 years.


Asunto(s)
Anemia de Diamond-Blackfan/genética , Secuencia de Bases , Resistencia a Medicamentos/genética , Mutación del Sistema de Lectura , Proteínas Ribosómicas/genética , Eliminación de Secuencia , Adolescente , Aloinjertos , Anemia de Diamond-Blackfan/terapia , Niño , Preescolar , Resultado Fatal , Femenino , Trasplante de Células Madre Hematopoyéticas , Humanos , Recién Nacido , Líbano , Esteroides
4.
Am J Clin Nutr ; 110(6): 1456-1464, 2019 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-31504095

RESUMEN

BACKGROUND: To accurately assess micronutrient status, it is necessary to characterize the effects of inflammation and the acute-phase response on nutrient biomarkers. OBJECTIVE: Within a norovirus human challenge study, we aimed to model the inflammatory response of C-reactive protein (CRP) and α-1-acid glycoprotein (AGP) by infection status, model kinetics of micronutrient biomarkers by inflammation status, and evaluate associations between inflammation and micronutrient biomarkers from 0 to 35 d post-norovirus exposure. METHODS: Fifty-two healthy adults were enrolled into challenge studies in a hospital setting and followed longitudinally; all were exposed to norovirus, half were infected. Post hoc analysis of inflammatory and nutritional biomarkers was performed. Subjects were stratified by inflammation resulting from norovirus exposure. Smoothed regression models analyzed the kinetics of CRP and AGP by infection status, and nutritional biomarkers by inflammation. Linear mixed-effects models were used to analyze the independent relations between CRP, AGP, and biomarkers for iron, vitamin A, vitamin D, vitamin B-12, and folate from 0 to 35 d post-norovirus exposure. RESULTS: Norovirus-infected subjects had median (IQR) peak concentrations for CRP [16.0 (7.9-29.5) mg/L] and AGP [0.9 (0.8-1.2) g/L] on day 3 and day 4 postexposure, respectively. Nutritional biomarkers that differed (P < 0.05) from baseline within the inflamed group were ferritin (elevated day 3), hepcidin (elevated days 2, 3), serum iron (depressed days 2-4), transferrin saturation (depressed days 2-4), and retinol (depressed days 3, 4, and 7). Nutritional biomarker concentrations did not differ over time within the uninflamed group. In mixed models, CRP was associated with ferritin (positive) and serum iron and retinol (negative, P < 0.05). CONCLUSION: Using an experimental infectious challenge model in healthy adults, norovirus infection elicited a time-limited inflammatory response associated with altered serum concentrations of certain iron and vitamin A biomarkers, confirming the need to consider adjustments of these biomarkers to account for inflammation when assessing nutritional status. These trials were registered at clinicaltrials.gov as NCT00313404 and NCT00674336.


Asunto(s)
Biomarcadores/sangre , Infecciones por Caliciviridae/sangre , Micronutrientes/sangre , Adulto , Proteína C-Reactiva/análisis , Proteína C-Reactiva/inmunología , Infecciones por Caliciviridae/inmunología , Infecciones por Caliciviridae/virología , Femenino , Ferritinas/sangre , Ácido Fólico/sangre , Humanos , Hierro/sangre , Estudios Longitudinales , Masculino , Norovirus/fisiología , Vitamina A/sangre , Vitamina D/sangre
5.
Blood Cells Mol Dis ; 76: 72-77, 2019 05.
Artículo en Inglés | MEDLINE | ID: mdl-30827762

RESUMEN

In hereditary hemochromatosis, iron overload is associated with homozygosity for the p.C282Y mutation. A second mutation, p.H63D, occurs at significant frequencies in Europe, North Africa, the Middle East and Asia. Early studies in Sri Lanka indicated that the variant had arisen independently, suggesting that it had been the subject of selective pressure. However, its role in iron absorption is unclear. In a survey of 7526 Sri Lankan secondary school students, we determined hemoglobin genotype and measured red cell indices, serum ferritin, transferrin receptor, iron zinc protoporphyrin and hepcidin. These variables were compared according to the presence or absence of the p.H63D variant in a subset of 1313 students for whom DNA samples were available. Students were classified as having low red cell indices if they had an MCV <80 fl and/or MCH <27 pg. Hetero and/or homozygosity for the p.H63D variant was more common in students with normal than low red cell indices (16.4% and 11.9% respectively; p = 0.019). Iron biomarkers and red cell indices were greater in children with the p.H63D variant than in normal and this was statistically significant for MCV (p = 0.046). Our findings suggest that selective pressure by mild iron deficiency contributes to the high frequencies of the p.H63D variant.


Asunto(s)
Alelos , Variación Genética , Proteína de la Hemocromatosis/genética , Hierro/metabolismo , Adolescente , Anemia Ferropénica , Niño , Índices de Eritrocitos , Hemocromatosis , Humanos , Selección Genética , Sri Lanka
7.
Nat Commun ; 8(1): 403, 2017 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-28864822

RESUMEN

Hepcidin regulates systemic iron homeostasis. Suppression of hepcidin expression occurs physiologically in iron deficiency and increased erythropoiesis but is pathologic in thalassemia and hemochromatosis. Here we show that epigenetic events govern hepcidin expression. Erythropoiesis and iron deficiency suppress hepcidin via erythroferrone-dependent and -independent mechanisms, respectively, in vivo, but both involve reversible loss of H3K9ac and H3K4me3 at the hepcidin locus. In vitro, pan-histone deacetylase inhibition elevates hepcidin expression, and in vivo maintains H3K9ac at hepcidin-associated chromatin and abrogates hepcidin suppression by erythropoietin, iron deficiency, thalassemia, and hemochromatosis. Histone deacetylase 3 and its cofactor NCOR1 regulate hepcidin; histone deacetylase 3 binds chromatin at the hepcidin locus, and histone deacetylase 3 knockdown counteracts hepcidin suppression induced either by erythroferrone or by inhibiting bone morphogenetic protein signaling. In iron deficient mice, the histone deacetylase 3 inhibitor RGFP966 increases hepcidin, and RNA sequencing confirms hepcidin is one of the genes most differentially regulated by this drug in vivo. We conclude that suppression of hepcidin expression involves epigenetic regulation by histone deacetylase 3.Hepcidin controls systemic iron levels by inhibiting intestinal iron absorption and iron recycling. Here, Pasricha et al. demonstrate that the hepcidin-chromatin locus displays HDAC3-mediated reversible epigenetic modifications during both erythropoiesis and iron deficiency.


Asunto(s)
Regulación de la Expresión Génica , Hepcidinas/genética , Histona Desacetilasas/metabolismo , Histonas/metabolismo , Acetilación , Secuencias de Aminoácidos , Animales , Epigénesis Genética , Eritropoyetina/genética , Eritropoyetina/metabolismo , Hepcidinas/metabolismo , Histona Desacetilasas/genética , Histonas/química , Humanos , Deficiencias de Hierro , Masculino , Ratones Endogámicos C57BL , Regiones Promotoras Genéticas
8.
Am J Hematol ; 92(2): 196-203, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-27883199

RESUMEN

Anemia affects over 800 million women and children globally. Measurement of hepcidin as an index of iron status shows promise, but its diagnostic performance where hemoglobinopathies are prevalent is unclear. We evaluated the performance of hepcidin as a diagnostic test of iron deficiency in adolescents across Sri Lanka. We selected 2273 samples from a nationally representative cross-sectional study of 7526 secondary schoolchildren across Sri Lanka and analyzed associations between hepcidin and participant characteristics, iron indices, inflammatory markers, and hemoglobinopathy states. We evaluated the diagnostic accuracy of hepcidin as a test for iron deficiency with estimation of the AUCROC , sensitivity/specificity at each hepcidin cutoff, and calculation of the Youden Index to find the optimal threshold. Hepcidin was associated with ferritin, sTfR, and hemoglobin. The AUCROC for hepcidin as a test of iron deficiency was 0.78; hepcidin outperformed Hb and sTfR. The Youden index-predicted cutoff to detect iron deficiency (3.2 ng/mL) was similar to thresholds previously identified to predict iron utilization and identify deficiency in African populations. Neither age, sex, nor α- or ß-thalassemia trait affected diagnostic properties of hepcidin. Hepcidin pre-screening would prevent most iron-replete thalassemia carriers from receiving iron whilst still ensuring most iron deficient children were supplemented. Our data indicate that the physiological relationship between hepcidin and iron status transcends specific populations. Measurement of hepcidin in individuals or populations could establish the need for iron interventions. Am. J. Hematol. 92:196-203, 2017. © 2016 Wiley Periodicals, Inc.


Asunto(s)
Anemia Ferropénica/diagnóstico , Hemoglobinopatías/sangre , Hepcidinas/sangre , Adolescente , Anemia Ferropénica/sangre , Anemia Ferropénica/complicaciones , Anemia Ferropénica/genética , Niño , Estudios Transversales , Ensayo de Inmunoadsorción Enzimática , Femenino , Hemoglobinopatías/complicaciones , Hemoglobinopatías/genética , Hemoglobinas/análisis , Hemoglobinas/genética , Humanos , Masculino , Sensibilidad y Especificidad , Sri Lanka , Adulto Joven
9.
Br J Haematol ; 175(2): 318-330, 2016 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-27432187

RESUMEN

Accurate diagnosis of rare inherited anaemias is challenging, requiring a series of complex and expensive laboratory tests. Targeted next-generation-sequencing (NGS) has been used to investigate these disorders, but the selection of genes on individual panels has been narrow and the validation strategies used have fallen short of the standards required for clinical use. Clinical-grade validation of negative results requires the test to distinguish between lack of adequate sequencing reads at the locations of known mutations and a real absence of mutations. To achieve a clinically-reliable diagnostic test and minimize false-negative results we developed an open-source tool (CoverMi) to accurately determine base-coverage and the 'discoverability' of known mutations for every sample. We validated our 33-gene panel using Sanger sequencing and microarray. Our panel demonstrated 100% specificity and 99·7% sensitivity. We then analysed 57 clinical samples: molecular diagnoses were made in 22/57 (38·6%), corresponding to 32 mutations of which 16 were new. In all cases, accurate molecular diagnosis had a positive impact on clinical management. Using a validated NGS-based platform for routine molecular diagnosis of previously undiagnosed congenital anaemias is feasible in a clinical diagnostic setting, improves precise diagnosis and enhances management and counselling of the patient and their family.


Asunto(s)
Anemia/diagnóstico , Anemia/genética , Predisposición Genética a la Enfermedad , Pruebas Genéticas , Biología Computacional/métodos , Manejo de la Enfermedad , Estudios de Asociación Genética , Pruebas Genéticas/métodos , Pruebas Genéticas/normas , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Lactante , Masculino , Mutación , Polimorfismo de Nucleótido Simple , Enfermedades Raras , Reproducibilidad de los Resultados , Flujo de Trabajo
10.
Blood ; 125(5): 873-80, 2015 Jan 29.
Artículo en Inglés | MEDLINE | ID: mdl-25519750

RESUMEN

Hemoglobin E (HbE) ß-thalassemia is the most common severe thalassemia syndrome across Asia, and millions of people are carriers. Clinical heterogeneity in HbE ß-thalassemia is incompletely explained by genotype, and the interaction of phenotypic variation with hepcidin is unknown. The effect of thalassemia carriage on hepcidin is also unknown, but it could be relevant for iron supplementation programs aimed at combating anemia. In 62 of 69 Sri Lankan patients with HbE ß-thalassemia with moderate or severe phenotype, hepcidin was suppressed, and overall hepcidin inversely correlated with iron accumulation. On segregating by phenotype, there were no differences in hepcidin, erythropoiesis, or hemoglobin between severe or moderate disease, but multiple linear regression showed that erythropoiesis inversely correlated with hepcidin only in severe phenotypes. In moderate disease, no independent predictors of hepcidin were identifiable; nevertheless, the low hepcidin levels indicate a significant risk for iron overload. In a population survey of Sri Lankan schoolchildren, ß-thalassemia (but not HbE) trait was associated with increased erythropoiesis and mildly suppressed hepcidin, suggesting an enhanced propensity to accumulate iron. In summary, the influence of erythropoiesis on hepcidin suppression associates with phenotypic disease variation and pathogenesis in HbE ß-thalassemia and indicates that the epidemiology of ß-thalassemia trait requires consideration when planning public health iron interventions.


Asunto(s)
Hemoglobina E/genética , Hepcidinas/genética , Sobrecarga de Hierro/genética , Globinas beta/genética , Talasemia beta/genética , Adolescente , Adulto , Portador Sano , Estudios de Casos y Controles , Niño , Preescolar , Eritropoyesis/genética , Femenino , Regulación de la Expresión Génica , Genotipo , Hemoglobina E/metabolismo , Hepcidinas/metabolismo , Humanos , Hierro/metabolismo , Sobrecarga de Hierro/etiología , Sobrecarga de Hierro/metabolismo , Sobrecarga de Hierro/patología , Modelos Lineales , Masculino , Persona de Mediana Edad , Mutación , Fenotipo , Índice de Severidad de la Enfermedad , Sri Lanka , Reacción a la Transfusión , Globinas beta/metabolismo , Talasemia beta/metabolismo , Talasemia beta/patología , Talasemia beta/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA